Enteroendocrine L cells secrete the incretin hormone glucagon-like peptide-1 (GLP-1), and they also express the a7 nicotinic acetylcholine receptor (a7nAChR), which may regulate GLP-1 secretion. Here, GTS-21, a selective a7nAChR agonist, was used to examine the effect of a7nAChR activation in L-cell lines, mouse intestinal primary cell cultures, and C57BL/6 mice. GTS-21 stimulated GLP-1 secretion in vitro, and this effect was attenuated by an a7nAChR antagonist or by a7nAChR-specific small interfering RNA. Under in vitro cell culture conditions of glucotoxicity, GTS-21 restored GLP-1 secretion and improved L-cell viability while also acting in vivo to raise levels of circulating GLP-1 in mice. To assess potential signaling mechanisms underlying these actions of GTS-21, we first monitored Ca
G lucagon-like peptide-1 (GLP-1) is an incretin hormone that is produced mainly by enteroendocrine L cells lining the intestinal mucosa (1) . GLP-1 binds its G protein-coupled receptors (GLP-1Rs) on pancreatic b cells to stimulate insulin secretion (2) , and it also acts at the GLP-1R on brainstem and vagal afferent sensory neurons to control energy homeostasis (3, 4) . Circulating GLP-1 has a short half-life because it is rapidly degraded by the enzyme dipeptidyl peptidase-4. Therefore, drugs that mimic the action of native GLP-1 or that inhibit GLP-1 degradation have become important therapies for type 2 diabetes mellitus (T2DM) (5, 6) .
L cells are located predominantly in the distal ileum and colon. L-cell function is influenced by luminal nutrients, hormones, inflammation, and vagal nerve regulation (7) . With apical processes facing the gut lumen, L cells directly sense nutrient levels in the intestine. Nutrient ingestion results in a biphasic pattern of GLP-1 secretion (8) . The initial secretion is mediated through a neuro/endocrine pathway, which involves vagal activity and the secretion of gastric inhibitory polypeptide (9, 10) .
Delayed secretion involves the direct detection of luminal nutrients by L cells (11) . L cells are generated from stem cells at the base of intestinal crypts, and L-cell number can be augmented by dietary fiber, short-chain fatty acids, polysaccharides, and the gut microbiota (12) (13) (14) . However, L-cell function and viability are negatively influenced by glucotoxicity and lipotoxicity, both factors that are implicated in the pathogenesis of T2DM (15) (16) (17) . On the basis of current knowledge, agents that stimulate GLP-1 secretion by promoting L-cell differentiation and/or by increasing L-cell numbers likely represent promising therapies to improve glycemic control in T2DM (18, 19) .
The a7 nicotinic acetylcholine receptor (a7nAChR) forms a Ca 2+ -permeant pentameric ligand-gated cation channel (20) . These a7 receptors are widely expressed in neuronal and nonneuronal cells, and several a7nAChR-selective agonists (e.g., GTS-21, PNU-282987, and TC-5619) are currently being tested in clinical trials of neurologic and psychiatric diseases (21) . Although acetylcholine released from vagal efferent nerves is known to regulate GLP-1 secretion through activation of L-cell muscarinic receptors (22) , a7nAChR expression was recently described in the enteroendocrine STC-1 cell line (23) . However, the potential role of these nicotinic receptors in the regulation of GLP-1 secretion or L-cell viability is unknown. Thus, to investigate a7nAChR signaling in the context of enteroendocrine cell function, we took advantage of intestinal cell lines of mouse (GLUTag, STC-1) or human (NCI-H716) origin that are widely used to study mechanisms controlling the secretion of GLP-1. Although none of these cell lines represents a perfect model of native L cells (24) , the GLUTag cells appear to be quite well differentiated, and they recapitulate the responsiveness of primary intestinal cell cultures to physiological and pharmacological GLP-1 secretagogues (25, 26) . Here, we report a7nAChR regulation of L-cell GLP-1 secretion and L-cell viability, as studied using not only GLUTag, NCI-H716, and STC-1 cells but also mouse intestinal primary cell cultures. First, we confirmed a7nAChR expression in GLUTag, NCI-H716, and STC-1 cells and L cells of mouse intestinal primary cell cultures and small intestine. Next, we used GTS-21, an a7nAChR-selective agonist, to demonstrate the effects of a7nAChR activation on GLP-1 secretion and L-cell viability in the absence or presence of glucotoxicity. Using selective pharmacological inhibitors, we also examined the role of Ca 2+ , cAMP, and the phosphatidylinositol 3-kinase (PI3K)-protein kinase B (Akt)-mammalian target of rapamycin (mTOR) pathways in regulating GLP-1 secretion and L-cell viability. Finally, we administered GTS-21 by intraperitoneal injection to demonstrate its in vivo GLP-1 secretagogue action. Collectively, these results demonstrate that under conditions of in vitro glucotoxicity, GTS-21 restores GLP-1 secretion and L-cell viability while also acting in vivo to raise circulating levels of GLP-1. 
Materials and Methods

Animals and reagents
Cell cultures
STC-1 and NCI-H716 cells were purchased from American Type Culture Collection (Manassas, VA). STC-1 cells were cultured in DMEM media (25 mM of glucose) with 10% fetal bovine serum (FBS) and 1% (v/v) penicillin (100 U/mL) and streptomycin (100 mg/mL) (pen-strep). NCI-H716 cells were grown in RPMI 1640 medium with 10% FBS and 1% penstrep. NCI-H716 cell adhesion was initiated by plating the cells on Matrigel Basement Membrane (catalog no. 354234; BD Biosciences, Bedford, MA) in DMEM supplemented with 10% FBS, 2 mm L-glutamine, and 1% (v/v) pen-strep. GLUTag cells (34) were obtained from Dr. D.J. Drucker (University of Toronto) and cultured in DMEM (5.5 mM of glucose) supplemented with 10% FBS and 1% (v/v) pen-strep. Culture media of GLUTag and STC-1 were exchanged every 3 days, and cells were trypsinized and reseeded when 80% confluence was reached. Newborn mice (C57BL/6) were used for preparation of mixed primary intestinal cell cultures enriched with L cells as described previously (35) .
GLP-1 secretion assay
Two days before each experiment, cells plated in 12-well culture plates coated with Matrigel (BD Biosciences) were allowed to reach 75% to 85% confluence. On the day of the experiment, cells were washed twice with glucose-free KrebsRinger medium containing (in mmol/L) 120 NaCl, 5 KCl, 2 CaCl 2 , 1 MgCl 2 , 22 NaHCO 3 , and 0.1 Diprotin A, gassed with 95% O 2 /5% CO 2 for 10 minutes, and then supplemented with 0.5% (w/v) BSA. Experiments were performed by incubating the cells in Krebs-Ringer medium containing GTS-21 for 2 hours at 37°C in a tissue culture incubator. For some experiments, cells were pretreated with a-BgTX, LY294002, Akt1/2 kinase inhibitor, rapamycin, BAPTA-AM, and PO 4 -AM 3 for 30 minutes in Krebs-Ringer medium before GTS-21 stimulation. At the end of each incubation, media were collected and centrifuged to remove any floating cells. The adherent cells were then lysed using RIPA buffer, and lysates were analyzed for total protein content using the Bradford assay (Bio-Rad Laboratories, Hercules, CA). Bioactive GLP-1 levels in the supernatants were determined by ELISA. Each experiment was repeated three times, and levels of secreted GLP-1 were normalized relative to total protein content expressed as a percentage of levels present in unstimulated control cells. Preliminary studies demonstrated that these signaling inhibitors (LY294002, Akt1/2 inhibitor, and rapamycin) did not alter GLP-1 secretion under the experimental conditions described here.
Cell viability assay
Cell viability was determined using the 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT; catalog no. 298-936-1; Thermo Fisher Scientific) colorimetric assay. Initially, cells were seeded in 96-well plates (10,000 cells per well) so that the indicated test compounds could be evaluated in triplicate assays while maintained in a tissue culture incubator. After the indicated treatment period was reached, 100 mL of 0.5 mg/mL MTT was added to each well. Cells were then incubated for an additional 4 hours at 37°C in a tissue culture incubator. MTT absorbance was then measured at 570 nm by a plate reader (Multiskan Ascents 354; Thermo LabSystems, Grand Island, NY).
Induction of glucotoxicity
Glucotoxicity was induced by exposure of cells to 25.6 mM (for GLP-1 secretion) or 30.6 mM (for cell viability) of glucose for 72 hours. Every 24 hours, the cell culture media were refreshed. For GLP-1 secretion experiments, cells were then washed and treated with GTS-21 for 2 hours in Krebs-Ringer medium after induction of glucotoxicity. In some experiments, cells were incubated with a-BgTX for 30 minutes before GTS-21 stimulation. For cell viability assays after induction of glucotoxicity, cells were washed with 5.6 mM of glucose culture medium 6 GTS-21 for 24 hours. To control for osmotic effects of high glucose, equimolar concentrations of mannitol were used.
RT-PCR assay
Total RNA was isolated from cells using the TRIzol method (Gibco Brl; Life Technologies). Total RNA (2 mg) was converted to cDNA using an iScript cDNA Synthesis Kit (Bio-Rad Laboratories) and a thermal cycler. Reverse transcriptionnegative samples were used to confirm the absence of genomic DNA. PCR was performed with the Step One Plus Real-Time PCR System (Applied Biosystems, Foster City, CA). The primers for mouse a7nAChR were 5 0 -ATCTGGGCATTGC-CAGTATC-3 0 (forward) and 5 0 -TCCCATGAGATCCCATT-CTC-3 0 (reverse; predicted 199-bp product). The primers for human a7nAChR were 5 0 -CCCGGCAAGAGGAGTGAAA-GGT-3 0 (forward) and 5 0 -TGCAGATGATGGTGAAGACC-3 0 (reverse; predicted 843-bp product). A sample containing all reaction reagents except cDNA was used as the RT-PCR negative control in each experiment. Amplified PCR products were visualized on 2% agarose gels to determine product sizes and the specificity of amplification.
Cytosolic Ca 2+ and cAMP assays
Cells were virally transduced to express the genetically encoded biosensor YC3.6 (36) for cytosolic Ca 2+ measurements or H188 for cytosolic cAMP measurements (37) . Measurements were performed 2 days after transduction in assays of fluorescence resonance energy transfer. Dynamic changes of [Ca 2+ ] i or [cAMP] i were monitored in real time by imaging single cells plated on glass coverslips 1 day before each assay. For all assays, tissue culture medium was removed and replaced with a standard extracellular solution containing (in mM) 138 NaCl, 5.6 KCl, 2.6 CaCl 2 , 1.2 MgCl 2 , and 10 HEPES (adjusted to pH 7.4 with NaOH) and supplemented with 5.6 mM of glucose. Cells on glass coverslips were then transferred to a temperature-controlled imaging chamber (QE-1; Warner Instruments, Hamden, CT) mounted on a Nikon Ti microscope while maintained at 37°C. Test solutions delivered to the chamber were prewarmed using an in-line heater (SH-27B; Warner Instruments), and the chamber contents were constantly perfused through the chamber at a rate of 2 mL/min using a peristaltic pump (RP-1; Rainin Dynamax, Oakland, CA). MetaFluor software (Molecular Devices, San Jose, CA) was used to control excitation light from a PTI (London, ON, Canada) DeltaRam monochromator, and images were acquired through a Dual-View beamsplitter (MAG Biosystems, BioVision Technologies, Exton, PA) using a Cascade 512B camera (Photometrics, Tuscon, AZ). Fluorescence resonance energy transfer-based measurements for both biosensors were obtained when using excitation light at 440 nm while monitoring the emission light measured simultaneously at 485 and 535 nm. An oil-immersion Nikon 603 objective was used to acquire these images. Data were exported from MetaFluor into Origin 15 software (OriginLab, Northampton, MA) for further processing, plotting, and statistical analysis.
Western blot assays
Cells were lysed on ice using protein lysis buffer containing a protease inhibitor cocktail (Roche, Indianapolis, IN). Samples were then centrifuged at 12,000 rpm at 4°C for 5 minutes. Equal amounts of protein were resolved by SDS-PAGE and transferred onto polyvinylidene difluoride membranes. After blocking with 5% nonfat milk, membranes were probed with the primary and secondary antibodies listed above so that enhanced chemiluminescence-based detection of these proteins could be achieved. Detection of b-actin was used as a loading control.
Immunocytochemistry
Cells were grown in 96-well plates coated with Matrigel. The medium was removed, and cells were rinsed with PBS and fixed in paraformaldehyde solution for 5 minutes. Intestinal tissue immediately proximal and distal to the appendix was extracted after euthanization, carefully cleaned of fat, fixed, and embedded in paraffin. These paraffin sections were deparaffinized in xylene and then hydrated in serial alcohol solutions. Fixed cells and tissue sections were incubated with 5% normal donkey serum for 1 hour. Cell and tissue sections were then incubated overnight at 4°C with the primary antibodies for GLP-1 [goat polyclonal antibody; catalog no. sc-7985-R; 1:50 dilution; Santa Cruz Biotechnology (32)] and the a7nAChR [rabbit polyclonal antibody; catalog no. sc-5544; 1:50 dilution; Santa Cruz Biotechnology (30)]. After three rinses with PBS, cells and sections were incubated 1 hour at room temperature with the indicated secondary antibodies comprising an Alexa Fluor 488-conjugated donkey anti-rabbit IgG (1:200 dilution; Abcam) or an Alexa Fluor 594-conjugated donkey anti-goat IgG (1:200 dilution; Thermo Fisher Scientific). Cells and sections were then gently rinsed three times with PBS. Finally, Fluoroshield mounting medium was applied, after which samples were imaged by fluorescence immunocytochemistry using a Nikon Eclipse TE2000-U microscope equipped with a Nikon CCD camera.
Small interfering RNA transfection assays a7nAChR or nontargeting (scrambled) small interfering RNA (siRNA) was delivered by transfection of GLUTag or STC-1 cells using a transfection reagent, as described in the manufacturer's protocol (Santa Cruz Biotechnology). Forty-eight hours after transfection, expression levels of a7nAChR mRNA and protein were measured to determine the a7nAChR knockdown efficiency. Fluorescein-conjugated control siRNA was used to monitor transfection efficiency by fluorescence microscopy. Transfected cells were washed and treated 6 GTS-21 (75 mM) for 2 hours, and media were collected to monitor GLP-1 secretion.
Effects of GTS-21 on circulating levels of GLP-1
To monitor effects of GTS-21 on GLP-1 secretion in vivo, C57BL/6 mice were administered GTS-21 by intraperitoneal injection at doses of 2, 4, and 8 mg/kg. Serum levels of GLP-1 at the indicated time points after injection were determined by ELISA using the kit described above.
Statistical analysis
Statistical analyses were performed using SPSS software (SPSS Inc., Chicago, IL). Continuous variables were first tested for normality and equality of variances. The results are expressed as the means 6 SEM or shown as box and whisker plots from experiments run in triplicate, with the number of independent experiments indicated in the figure legends. Box and whisker plots show mean (solid square), 25% to 75% range (open box), median (line across open box), and minimum and maximum values (whiskers). One-way ANOVA with the post hoc Bonferroni test was used in multiple comparisons. Significance is indicated at P , 0.05.
Results
a7nAChR expression in L-cell lines and murine intestine
Expression of a7nAChR mRNA in the enteroendocrine L-cell lines GLUTag, STC-1, and NCI-H716 was determined by RT-PCR. As shown in Fig. 1A , PCR products of the predicted molecular sizes for the a7nAChR (199 bp for murine cells and 843 bp for human cells) were obtained using all L-cell lines. As a positive control, we used mRNA from mouse brain, which is known to express a high level of a7nAChR. Expression of a7nAChR protein in L cells was also evaluated by Western blot analysis. A clear band with a molecular weight of approximately 55 kD was detected in GLUTag, STC-1, and NCI-H716 cell lysates (Fig. 1B) . a7nAChR protein from mouse brain was again used as a positive control (Fig. 1B) . Next, immunofluorescence microscopy was performed to image a7nAChR expression in primary mouse small intestinal cell cultures, sections of mouse ileum, and GLUTag or STC-1 cells that were doublestained for GLP-1 and a7nAChR. Cells demonstrated immune-positive staining for GLP-1 (red) and a7nAChR (green), and merged images validated their colocalization (Fig. 2) . Similar findings were obtained with NCI-H716 cells (data not shown). L cells, identified by GLP-1 staining, are sparse in the primary intestinal epithelial cell cultures and intestinal villi. However, most cells staining positive for GLP-1 also expressed a7nAChR (Fig. 2) .
a7nAChR-regulated GLP-1 secretion
The role of a7nAChR in the regulation of GLP-1 secretion was evaluated using GLUTag, STC-1, and NCI-H716 cell lines, as well as mixed intestinal mouse primary epithelial cell cultures treated for 2 hours with or without GTS-21. For comparison, basal GLP-1 secretion was measured in glucose-free Krebs-Ringer medium in 12-well plates for each cell type. Basal [GLP-1] was 30.5 6 2.1 pg/mL in GLUTag (n = 18), 25.6 6 3.9 pg/mL in STC-1 (n = 18), 40.1 6 3.2 pg/mL in NCI-H716 (n = 19), and 14.8 6 2.7 pg/mL in intestinal epithelial cell cultures (n = 12).
The dose-dependent action of GTS-21 in assays of GLP-1 secretion is shown in Fig. 3A . GTS-21 significantly increased GLP-1 secretion, indicating a functional role for a7nAChR in L cells. To confirm that GTS-21-induced GLP-1 secretion was a result of a7nAChR activation, GLUTag, STC-1, NCI-H716, and mixed primary intestinal epithelial cell cultures were preincubated with the a7nAChR antagonist a-BgTX (100 nM) before GTS-21 stimulation. For all cell types tested, the GTS-21-stimulated GLP-1 secretion was abrogated after a-BgTX pretreatment (Fig. 3B) . Next, we examined whether siRNA knockdown of a7nAChR inhibited GTS-21-stimulated GLP-1 secretion. First, we confirmed that treatment with a7nACHR siRNA resulted in decreased expression of a7nAChR mRNA (Fig. 4A) and protein (Fig. 4B ) in GLUTag and STC-1 cells. We also demonstrated that knockdown of a7nAChR attenuated the ability of GTS-21 to stimulate GLP-1 release in GLUTag and STC-1 cells (Fig. 4C and 4D, respectively) .
GTS-21 counteracted L-cell glucotoxicity
Impaired GLP-1 secretion in T2DM appears to be caused in part by the effects of chronic hyperglycemia, which generates glucotoxicity. Here, GLUTag cells were exposed to 25.6 mM of glucose for 72 hours to induce glucotoxicity so a potential restorative effect of GTS-21 on GLP-1 secretion could be examined. Glucotoxic cell culture conditions decrease basal GLP-1 secretion in GLUTag cells, and this inhibition was reversed by treatment with GTS-21 (Fig. 5A) . As expected, pretreatment of GLUTag cells with a-BgTX counteracted this secretagogue action of GTS-21. These data provide an indication that a7nAChR activation restores GLP-1 secretion to normal levels under conditions of glucotoxicity.
Chronic elevation of glucose or lipid levels may also affect L-cell viability in addition to effects on GLP-1 secretion. We therefore examined the effects of GTS-21 on L-cell viability using the MTT assay and GLUTag cells cultured in media that contained either normal or elevated concentrations of glucose. Under normoglycemic conditions, treatment with GTS-21 for 24 hours enhanced the number and viability of GLUTag cells (Fig. 5B) . Treatment with a-BgTX (100 nM) alone had no effect on cell viability but fully abrogated the effects of GTS-21 on cell viability and number. Several lines of evidence suggest that increasing the number of intestinal L cells might represent a promising mechanism for augmenting GLP-1 secretion and improving glycemic control (18) . To further characterize the effects of GTS-21 on L-cell viability, we examined its effects under glucotoxic culture conditions (16, 17) . In these experiments, GLUTag cells were exposed to 30.6 mM of glucose for 72 hours, resulting in decreased cell viability (Fig. 5C) . Increasing concentrations of GTS-21 ameliorated the deleterious effects of glucotoxicity on cell viability, and a-BgTX blocked this effect, thereby establishing that L-cell viability is under the control of a7nAChR. (38) , and it also exerts metabotropic effects through G protein signaling (39 was observed (Fig. 6A and 6B ). Although GLP-1 secretion has also been stimulated by cAMP (40), GTS-21 had no effect on [cAMP] i in GLUTag cells (Fig. 6C) . Thus, Ca 2+ but not cAMP mediates the action of GTS-21
GTS-21 increased [
to stimulate GLP-1 release.
PI3K/AKT/mTOR signaling was stimulated by GTS-21
The PI3K/Akt/mTOR signaling pathway is reported to be activated by a7nAChR agonists, and it is involved in the regulation of cell proliferation, survival, and metabolism. We found a significant increase in the levels of phosphorylated PI3K, Akt, and p70 S6K 2 hours after treatment of GLUTag cells with GTS-21 (Fig. 7A) . As predicted, pretreatment with a-BgTX reduced these actions of GTS-21 (Fig. 7A) , as was also the case for a PI3K inhibitor (LY294002), an Akt1/2 kinase inhibitor, and an mTOR inhibitor (rapamycin) (Fig. 7B) . However, none of these inhibitors of growth factor signaling pathways reduced GLP-1 secretion in response to GTS-21 (data not shown). In contrast, loading of cells with the membrane-permeable Ca 2+ chelator prodrug BAPTA-AM reduced GLP-1 secretion in response to GTS-21, whereas the negative control PO 4 -AM 3 that fails to buffer Ca 2+ was ineffective (Fig. 7C) . Surprisingly, activation of the PI3K/Akt/p70 S6K pathway by GTS-21 was reduced in BAPTA-AM-loaded cells but not in PO 4 -AM 3 -loaded cells (Fig. 7C) . Thus Ca 2+ serves as a permissive factor-or possibly a direct coupling factor-for GTS-21-stimulated growth factor signaling.
Effects of GTS-21 on circulating GLP-1
Finally, we tested whether GTS-21 stimulated GLP-1 secretion in vivo in C57BL/6 mice. Mice were injected intraperitoneally with 2, 4, and 8 mg/kg of GTS-21, and the circulating levels of GLP-1 were measured 1 hour later. As shown in Fig. 8A , there was a 34% increase in circulating levels of GLP-1 after administration of 2 mg/kg of GTS-21 and a 93% increase after administration of 4 mg/kg of GTS-21. Increasing the GTS-21 dose to 8 mg/kg had no additional significant effect. As shown in Fig. 8B , the increase in circulating GLP-1 level after administration of 4 mg/kg of GTS-21 was maintained for 4 hours.
Discussion
Findings reported here demonstrated expression of a7nAChR in L-cell lines that secrete GLP-1 and also in GLP-1-positive L cells of the mouse intestine. Expression of a7nAChR in human L cells has yet to be elaborated. Activation of a7nAChR increased GLP-1 secretion and enhanced L-cell viability in the presence or absence of glucotoxicity. Just as important, mice treated with GTS-21 showed an increase in circulating GLP-1 level in timeand dose-dependent manners. a7nAChR activation by GTS-21 induced GLP-1 release and enhanced L-cell viability, and these effects resulted from a stimulation of the Ca 2+ and PI3K/Akt/mTOR signaling pathways. A schematic model of the a7nAChR signaling pathway that we elucidated for L cells is shown in Fig. 9 . Interestingly, nicotine stimulates smooth muscle cell proliferation through a7nAChR-mediated activation of PI3K/Akt signaling (45) , and the PI3K/Akt/mTOR pathway is involved in vascular endothelial growth factor secretion from STC-1 cells (46) , thereby suggesting conserved mechanisms of a7nAChR growth factor-like signaling across different cell types.
Prior studies showed that GLP-1 secretion from L cells was maintained by vagal tone (10), but a potential role for a7nAChR was not documented. However, enteroendocrine cells can coexpress and release GLP-1, PYY, and neurotensin (47) , and vagal neurons innervating the small intestine of mice have been reported (48) . Potentially, vagal release of acetylcholine stimulates GLP-1 secretion through activation of the L-cell a7nAChR.
GLP-1 is conventionally viewed as a potent incretin hormone, and GLP-1 analogs or dipeptidyl peptidase-4 inhibitors are now used for the treatment of T2DM (5, 6). Although no GLP-1-releasing agent has been approved for use in humans with T2DM, this is an area of continued interest within the drug discovery community (7). In our in vitro studies of L cells reported here, a7nAChR activation by the selective agonist GTS-21 promoted GLP-1 secretion under normoglycemic conditions and also under conditions of glucotoxicity. Consistent with our data, a correlation between a7nAChR activity and improved glucose homeostasis was reported previously (49, 50) . Because a7nAChR agonists such as GTS-21 have shown safety and efficacy in clinical trials of nervous system diseases, they might constitute a novel strategy to achieve neuroprotective effects (21) . Extending on this idea, a7nAChR agonists may therefore be promising GLP-1-releasing agents for improving glucose homeostasis in T2DM. GLP-1R mRNA was previously identified in multiple organ systems, and beneficial extrapancreatic effects of GLP-1 exist (51, 52) . Therefore, by promoting GLP-1 secretion and activation of the GLP-1 receptor, a7nAChR agonists not only may indirectly promote insulin secretion but also may have beneficial effects in other tissues.
Reduced levels of plasma GLP-1 in patients with T2DM have been reported as well as reduced numbers of GLP-1-producing intestinal cells, and these alterations are positively correlated to obesity and insulin resistance (53) . Here, we report that a7nAChR stimulation for 24 hours promoted GLUTag cell viability. Moreover, the viability of GLUTag cells improved with a7nAChR stimulation in the presence of glucotoxicity. Because glucotoxicity induces apoptosis in GLUTag cells (17) , we propose that a7nAChR agonists enhance GLUTag cell viability through antiapoptotic effects, similar to their neuroprotective effects (42) . Furthermore, we propose that this beneficial effect is explained by a mechanism of convergent Ca 2+ and PI3K/Akt/mTOR signaling in L cells (Fig. 9) . Still, it is important to note that additional signaling mechanisms are potentially under the control of a7nAChR. For example, Janus kinase 2 (JAK2) mediates the neuroprotective (42) and beneficial glycemic effects of a7nAChR agonists (49) . And JAK2 is reported to be inhibitory for insulin secretion in rat islets (54) . In contrast to the central hypothesis presented here, in which GTS-21 exerts a direct action to promote L-cell viability (Fig. 9) , it is possible that L-cell a7nAChR activation leads to autocrine or paracrine factor release in the intestine, thereby leading to indirect stimulation of L-cell viability (55) . Modulation of L-cell number is a potentially novel therapeutic strategy to improve glycemic control (18) , thereby suggesting that a7nAChR stimulation might increase L-cell numbers in patients with T2DM. Because studies of other cell types revealed PI3K/Akt activation downstream of a7nAChR (42, 45, 56) , a PI3K/Akt/mTOR pathway might mediate a restorative action of GST-21 to improve L-cell viability under conditions of T2DM. Indeed, mTOR activation links energy supply with the production and secretion of GLP-1 in L cells (57) . Thus, future preclinical studies will focus on underlying mechanisms by which a7nAChR activation affects L-cell proliferation, apoptosis, and differentiation in animal models of T2DM.
Conclusion
Enteroendocrine L cells express a7nAChR, and activation of a7nAChR enhances GLP-1 secretion, an effect attributable to elevated levels of cytosolic [Ca 2+ ] i . -calmodulin (CaM) (41) and Janus kinase 2 (JAK2) (42) . Ca 2+ can also promote GLP-1 secretion directly or through Ca 2+ /calmodulin-dependent kinase II (CaMKII) (43) . The Ca 2+ chelator BAPTA-AM inhibits all depicted effects of GST-21. Numerous downstream effectors of the metabolically regulated mTOR complex 1 (mTORC1) (44) are involved in cell viability, and determining which pathways are important to L-cell biology requires further investigation.
Moreover, stimulation of a7nAChR enhances L-cell viability under glucotoxic conditions. Ca 2+ participates as a necessary cofactor to support PI3K/Akt/mTOR activation, whereas acute inhibition of these growth factor signaling pathways fails to alter GLP-1 secretion. Thus, such growth factor signaling pathways appear to be primary determinants of L-cell viability, survival, and cytoprotection. Because we found that GTS-21 elevated circulating levels of GLP-1 in vivo, it may be feasible to use selective a7nAChR agonists, or positive allosteric modulators, as GLP-1-releasing agents and/or L-cell trophic factors with potential therapeutic value in T2DM.
